TY - JOUR
T1 - Serial 18F-FDG PET for monitoring treatment response after allogeneic stem cell transplantation for myelofibrosis
AU - Derlin, Thorsten
AU - Alchalby, Haefaa
AU - Bannas, Peter
AU - Laqmani, Azien
AU - Ayuk, Francis
AU - Triviai, Ioanna
AU - Kreipe, Hans Heinrich
AU - Bengel, Frank M.
AU - Kröger, Nicolaus
N1 - Publisher Copyright:
Copyright © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Our objective was to assess the feasibility of 18F-FDG PET/CT for noninvasive monitoring of treatment response after allogeneic stem cell transplantation (SCT) for myelofibrosis. Methods: Twelve patients with myelofibrosis underwent 18F-FDG PET/CT before and after SCT. Bone marrow uptake, spleen uptake, and spleen size were assessed before and after SCT and compared with hematologic response criteria and bone marrow biopsies. Results: All patients who did not achieve complete remission remained PET-positive (P = 0.02). Extent of disease, bone marrow metabolism, spleen metabolism, and spleen volume decreased significantly in patients with complete remission (P = 0.03). PET/CT after SCT had a sensitivity of 1.0 (95% confidence interval [CI], 0.54-1.0), a specificity of 0.83 (95% CI, 0.36-1.0), a negative predictive value of 1.0 (95% CI, 0.48-1.0), and a positive predictive value of 0.86 (95% CI, 0.42-1.0) for diagnosis of residual disease. Conclusion: 18F-FDG PET/CT is feasible for noninvasive monitoring of treatment response after allogeneic SCT for myelofibrosis.
AB - Our objective was to assess the feasibility of 18F-FDG PET/CT for noninvasive monitoring of treatment response after allogeneic stem cell transplantation (SCT) for myelofibrosis. Methods: Twelve patients with myelofibrosis underwent 18F-FDG PET/CT before and after SCT. Bone marrow uptake, spleen uptake, and spleen size were assessed before and after SCT and compared with hematologic response criteria and bone marrow biopsies. Results: All patients who did not achieve complete remission remained PET-positive (P = 0.02). Extent of disease, bone marrow metabolism, spleen metabolism, and spleen volume decreased significantly in patients with complete remission (P = 0.03). PET/CT after SCT had a sensitivity of 1.0 (95% confidence interval [CI], 0.54-1.0), a specificity of 0.83 (95% CI, 0.36-1.0), a negative predictive value of 1.0 (95% CI, 0.48-1.0), and a positive predictive value of 0.86 (95% CI, 0.42-1.0) for diagnosis of residual disease. Conclusion: 18F-FDG PET/CT is feasible for noninvasive monitoring of treatment response after allogeneic SCT for myelofibrosis.
KW - Allogeneic
KW - F-FDG PET/CT
KW - Myelofibrosis
KW - Positron emission tomography
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=84991396411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991396411&partnerID=8YFLogxK
U2 - 10.2967/jnumed.115.166348
DO - 10.2967/jnumed.115.166348
M3 - Article
C2 - 27230931
AN - SCOPUS:84991396411
SN - 0161-5505
VL - 57
SP - 1556
EP - 1559
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 10
ER -